US 11,439,628 B2 · Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases

Abstract

The present invention relates to non-steriodal mineralocorticoid receptor (MR) and the pharmacology of mineralocorticoid receptor antagonists (MR Antagonists, MRAs). In particular, the invention relates to the use of MRAs alone and in combination preferably in combination with sGC stimulators and/or sGC activators for preparation of medicaments for the prevention and/or treatment of muscular or neuromuscular diseases, especially for the treatment of Duchenne Muscular Dystrophy (DMD).

Claims8

Dependent claims

A method for the treatment and/or prevention of Duchenne muscular dystrophy in a human or animal comprising administering a therapeutically effective amount of a non-steroidal mineralocorticoid receptor antagonist that is (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1, 6-naphthyridine-3-carboxamide according to formula (I)

or a pharmaceutically acceptable salt thereof to a human or animal in need thereof.

Dependencies are inferred from the claim text.

Facts

Application

17/051,923Filed 10 May 2019

Priority

EP 1817185711 May 2018

Published

US 2021/0121447 A129 Apr 2021

Granted

13 Sep 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/4375
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring…
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases

Life of this patent

Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases

Life of this patent

Abstract

Claims8